Early Options - A Provider's Guide to Medical Abortion Early Options - A Provider's Guide to Medical Abortion Early Options - A Provider's Guide to Medical Abortion
Home
Information About the Early Options Program
CME Information
Women's Experiences: Video Clips
Video Help
Back to prochoice.org
National Abortion Federation
References - Module 1: Pharmacological Approaches to Early Abortion
  1. Herrmann WL, Schindler AM, Wyss R, Bischoff P. Effects of the antiprogesterone RU 486 in early pregnancy and during the menstrual cycle. In: Beaulieu EE, Siegel S, eds. The Antiprogestin Steroid RU 486 and Human Fertility Control. New York, NY: Plenum; 1985:259-262.
     
  2. Gravanis A, Schaison G, George M, et al. Endometrial and pituitary responses to the steroidal anti-progestin RU 486 in post-menopausal women. J Clin Endocrinol Metab. 1984;60:156-163.
     
  3. Herrmann WL, Schindler AM, Wyss R, Bischoff P. Effects of the antiprogesterone RU 486 in early pregnancy and during the menstrual cycle. In: Beaulieu EE, Siegel S, eds. The Antiprogestin Steroid RU 486 and Human Fertility Control. New York, NY: Kluwer Academic/Plenum Publishers; 1985:179-198.
     
  4. Creinin MD. Medical abortion regimens: historical context and overview. Am J Obstet Gynecol. 2000;183(2)(suppl):S3-S9.
     
  5. Swahn ML, Cekan S, Wang G, Lujndstrom V, Bygdeman M. Pharmacokinetic and clinical studies of RU 486 for fertility regulation. In: Beaulieu EE, Siegel S, eds. The Antiprogestin Steroid RU 486 and Human Fertility Control. New York, NY: Plenum; 1985:249-258.
     
  6. Mifepristone [package insert]. Danco Laboratories LLC; 2000.
     
  7. Peyron R, Aubény E, Targosz V, et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med. 1993;328:1509-1513.
     
  8. Aubény E, Peyron R, Turpin CL, et al. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol. Int J Fertil Menopausal Stud. 1995;40(suppl):85-91.
     
  9. Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med. 1998;338:1241-1247.
     
  10. World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomized trial. Br J Obstet Gynaecol. 2000;107:524-530.
     
  11. Ngoc NT, Winikoff B, Clark S, et al. Safety, efficacy and acceptability of mifepristone-misoprostol abortion in Vietnam. Int Fam Plann Perspect. 1999;25:10-33.
     
  12. Winikoff B, Sivin I, Coyaji KJ, et al. Safety, efficacy and acceptability of medical abortion in China, Cuba and India: a comparative trial of mifepristone-misoprostol versus surgical abortion. Am J Obstet Gynecol. 1997;176:431-437.
     
  13. Heikinheimo O, Kekkonen R. Dose response relationships of RU 486. Ann Med. 1993;25:71-76.
     
  14. World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ. 1993;307:532-537.
     
  15. McKinley C, Thong KJ, Baird DT. The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Hum Reprod. 1993;8(9):1502-1505.
     
  16. Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997;90(1):88-92.
     
  17. El-Refaey H, Rajasekar R, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med. 1995;332:983-987.
     
  18. Kahn JG, Becker BJ, MacIsaac L, et al. The efficacy of medical abortion: a meta-analysis. Contraception. 2000;61:29-40.
     
  19. Ashok PW, Penney GC, Flett GM, Templeton A. An effective regimen for early medical abortion: a report of 2,000 consecutive cases. Hum Reprod. 1998;13:2962-2965.
     
  20. Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception. 1999;59:1-6.
     
  21. Schaff EA, Fielding SL, Eisinger SH, Stadalius LS, Fuller L. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception. 2000;61:41-46.
     
  22. Creinin MD, Fox MC, Teal S, Chen A, Meyn LA. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol 2004;103;851-9.
     
  23. Schaff EA, Fielding SL, Westhoff C, et al. Randomized trial of vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA. 2000;284:1948-1953.
     
  24. Schaff E, Stadalius LS, Eisinger SH, Franks P. Vaginal misoprostol administered at home after mifepristone (RU 486) for abortion. J Fam Pract. 1997;44:353-359.
     
  25. Newhall EP, Winikoff B. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions. Am J Obstet Gynecol. 2000;183(2)(suppl):S44-S53.
     
  26. Lipscomb GH, Bran D, McCord ML, Portera JC, Ling FW. Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate. Am J Obstet Gynecol. 1998;178:1354-1358.
     
  27. DeLoia JA, Stewart-Akers AM, Creinin MD. Effects of methotrexate: effects on trophoblast proliferation and local immune responses. Hum Reprod. 1998;13:1063-1069.
     
  28. Creinin MD, Darney PD. Methotrexate and misoprostol for early abortion. Contraception. 1993;48:339-348.
     
  29. Hausknecht RU. Methotrexate and misoprostol to terminate early pregnancy. N Engl J Med. 1995;333:537-540.
     
  30. Creinin MD, Vittinghoff E, Keder L, Darney PD, Tiller G. Methotrexate and misoprostol for early abortion: a multicenter trial. Contraception. 1996;53:321-327.
     
  31. Carbonell JLL, Velazco A, Varela L, Cabezas E, Fernandez C, Sanchez C. Misoprostol 3, 4, or 5 days after methotrexate for early abortion: a randomized trial. Contraception. 1997;56:169-174.
     
  32. Creinin MD, Carbonell JLL, Schwartz JL, Varela L, Tanda R. A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. Contraception. 1999;59:11-16.
     
  33. Creinin MD, Vittinghoff E, Schaff E, Klaisle C, Darney PD, Dean C. Medical abortion with oral methotrexate and vaginal misoprostol. Obstet Gynecol. 1997;90:611-616.
     
  34. Carbonell Esteve JL, Varela L, Velazco A, Tanda R, Sanchez C. 25 mg or 50 mg of oral methotrexate followed by vaginal misoprostol 7 days after for early abortion: a randomized trial. Gynecol Obstet Invest. 1999;47:182-187.
     
  35. Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med. 2001;344(1):38-47.
     
  36. Wiebe E, Dunn S, Guilbert E, Jacot F, Lugtig L. Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. Obstet Gynecol. 2002;99:813-819.
     
  37. Schaff EA, Eisinger SH, Franks P, Kim S. Methotrexate and misoprostol for early abortion. Fam Med. 1996;28:198-203.
     
  38. Crenin MD, Spitz IM. Use of various ultrasound criteria to evaluate the efficacy of mifepristone and misoprostol for medical abortion. Am J Obstet Gynecol. 1999;18:1419-1424.
     
  39. Carbonell JLL, Varela L, Velazco A, Fernandez C. The use of misoprostol for termination of early abortion. Contraception. 1997;55:165-168.
     
  40. Carbonell JLL, Varela L, Velazco A, Fernandez C, Sanchez C. The use of misoprostol for abortion at 9 weeks' gestation. Eur J Contraception Reprod Health Care. 1997;2:181-185.
     
  41. Carbonell JLL, Velazco A, Varela L, Cabezas E, Fernandez C, Sanchez C. Early abortion with 800 micrograms of misoprostol by the vaginal route. Contraception. 1999;59:219-225.
     
  42. Jain JK, Meckstroth KR, Mishell DR. Early pregnancy termination with intravaginally administered sodium chloride-moistened misoprostol tablets: historical comparison with mifepristone and oral misoprostol. Am J Obstet Gynecol. 1999;181:1368-1391.
     
  43. Goujard J. Mifepristone: risque teratogenes. In: Ceschon P, ed. L'interruption de grossesse depuis loi Veil: bilan et perspectives. Paris: Medecine-Sciences Flammarion; 1997:55-57.
     
  44. Fonesca W, Alencar AJC, Mota FSB, Coelho HLL. Misoprostol and congenital malformations. Lancet. 1991;338:356.
     
  45. Winikoff B, Ellertson C, Elul B, Sivin I. Acceptability and feasibility of early pregnancy termination by mifepristone-misoprostol: results of a large multicenter trial in the United States. Arch Fam Med. 1998;7:360-366.
     
  46. Henry J. Kaiser Family Foundation. Views of Women's Health Care Providers on Abortion: An Update on Mifepristone. Menlo Park, Calif: The Henry J Kaiser Foundation; 2000.
     
  47. Elul B. Mifepristone-misoprostol medical abortion: simplifying the regimen - preliminary results. Paper presented at: Annual Meeting of the American Public Health Association; November 1998; Washington, DC.
     
  48. Harvey SM, Beckman LJ, Castle MA, Coeytaux F. Knowledge and perceptions of medical abortion among potential users. Fam Plann Perspect. 1995;27(5):203-207.
     
  49. Winikoff B, Sivin I, Coyaji KJ, et al. The acceptability of medical abortion in China, Cuba, and India. Int Fam Plann Perspect. 1997;23:73-89.
     
  50. Baker A. Abortion and Options Counseling: A Comprehensive Reference. Granite City, Ill: The Hope Clinic for Women; 1995.
     
  51. Picker Institute. From the Patient's Perspective: Quality of Abortion Care [survey]. Menlo Park, Calif: Henry J Kaiser Family Foundation; 1999.

 
Click here to return to Module 1 - Pharmacological Approaches to Early Abortion.

©2005 Copyright National Abortion Federation
Disclaimer | Contact Us